Sorry, Your Requested Page Was Not Found.
Greetings! We apologize for the inconvenience, but the page, Press Release Esperion Launches U S Direct To Consumer Campaign To Accelerate Awareness Of Nexletol Bempedoic Acid Tablets And Increase Awareness Of Bad Cholesterol is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3 - 18 months after the created date. We prefer to keep content fresh and current and not keep old news. Thanks for visiting today.Search RobinsPost News & Noticias
Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”
Direct-to-Consumer (DTC) campaign, “VOQUEZNA Can Kick Some Acid,” to raise awareness of its powerful first-in-class treatment and encourage people to speak to their doctor about this new ... Read More
Esperion: FDA Approves Expanded Labels For NEXLETOL And NEXLIZET Tablets
(RTTNews) - Esperion (ESPR) on Friday announced that the U.S. Food and Drug Administration or FDA approved new label expansions for NEXLETOL (bempedoic acid) Tablets and NEXLIZET (bempedoic acid ... Read More
Esperion Shares Continue Rise After Friday's FDA Approval for Nexlizet, Nexletol
Esperion shares were up 16% to $2.67 after the company said Friday the U.S. Food and Drug Administration approved broad new label expansions for Nexletol bempedoic acid tablets and Nexlizet ... Read More
Esperion Therapeutics, Inc. (ESPR)
April 07, 2024 (GLOBE NEWSWIRE) -- Esperion ... the use of NEXLETOL NEXLETOL® (bempedoic acid) Tablet – New Labels Expand Treatable Population to ~70 Million Patients in U.S. – – First ... Read More
Why Is Heart Disease-Focused Esperion Therapeutics Stock Trading Higher On Monday?
Friday, the FDA approved broad new label expansions for Esperion Therapeutics Inc’s (NASDAQ:ESPR) NEXLETOL (bempedoic acid) Tablets and NEXLIZET ... expansions in the U.S., which will enable ... Read More
Expanded Label Officially Makes Bempedoic Acid a CVD Prevention Medication
Opens in a new tab or window The FDA approved label expansions for bempedoic acid (Nexletol ... president and CEO of Esperion, in the company press release. These wider approvals may help ... Read More
FDA approves expanded labels for Esperion's cholesterol drugs
ANN ARBOR, Mich. - Esperion (NASDAQ:ESPR) Therapeutics (NASDAQ:ESPR) announced today that the U.S. Food and Drug Administration (FDA) has approved new label expansions for its cholesterol-lowering ... Read More
Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”
Direct-to-Consumer (DTC) campaign, “VOQUEZNA Can Kick Some Acid,” to raise awareness of its powerful first-in-class treatment and encourage people to speak to their doctor about this new treatment ... Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus